Nonstimulant ADHD Treatment Option Approved for Adults
The FDA has approved Qelbree for the treatment of ADHD in adults 18 years of age and older.
Source: empr.com
Page 2 - Illness Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Illness Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Illness Scale Today - Breaking & Trending Today
FDA OKs New Nonstimulant Option for Adult ADHD
New selective norepinephrine reuptake inhibitor is no longer just for kids
Source: medpagetoday.com
Rising Social and Existential Uncertainty Linked to Mental Distress
A review of the research literature finds a positive association between uncertainty and mental distress such as depression and anxiety.
Source: madinamerica.com
Regular Assessment of Patient-Reported Factors Related to QOL Recommended in Patients With CML
Illness uncertainty, self-perceived burden, and QOL should be regularly assessed in patients with CML, with extra attention to illness uncertainty due to its importance in QOL.
Source: oncologynurseadvisor.com
Viloxazine Under Review for ADHD Treatment in Adults
The FDA has accepted for review the sNDA for viloxazine extended-release (Qelbree) for the treatment of ADHD in adults.
Source: empr.com